The ASX200 lost -3.8% in October with mid cap and small cap indices faring worse as 10-year bond yields climbed, while the gold price spiked
Tim Boreham highlights the success of Paradigm Biopharmaceuticals’ joint pain drug ahead of a capital raising
Overviews in raw numbers and calculations that might assist investors with assessing trends and currents that might not be apparent from daily volatility and movements
FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments
Independent Investment Research updates developments among Australia’s listed investment companies and provides comparative data
A glance through the latest expert views and predictions about commodities: UBS lowers lithium price forecasts; conversations on the ground in China; the impact of new Chinese policy on iron ore and base metals
The share market has not been kind to underperforming waste management and treatment businesses, reports Tim Boreham
Inghams Group has provided a surprisingly positive first half guidance upgrade, although not all brokers see a sustainable change in fortune
In this edition we return to the green theme as green deflation kicks in on the national energy market big time; global analysts forecast a slump in global electric vehicle demand; lithium price forecasts are hammered; and for a little light relief, the world’s first flying car comes to market
Endeavour Group saw the cost of living biting in the September quarter, as consumers trade down to cheaper liquor alternatives and eschew the pokies
